O10.05 FINAL ANALYSIS OF THE BELOB TRIAL (A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENT IN RECURRENT GLIOBLASTOMA) AND FIRST RADIOLOGY REVIEW RESULTS

INTRODUCTION: Treatment options for recurrent glioblastoma remain limited, with only modest activity of second line chemotherapy. Despite the absence of well controlled trials, bevacizumab is widely used for recurrent glioblastoma. Nonetheless, it remains unclear if the high response rates observed...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Taal, W., Oosterkamp, H.M., Walenkamp, A.M.E., Dubbink, H.J., Beerepoot, L.V., Hanse, M., Buter, J., Honkoop, A., Boerman, D., Vos, F.Y.F., Dinjens, W.N.M., Enting, R.H., Taphoorn, M.J.B., van den Berkmortel, F.W.P.J., Jansen, R., Brandsma, D., Bromberg, J.E., van Heuvel, I., Vernhout, R.M., van der Holt, B., van den Bent, M.J.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2014
Témata:
Oral Presentations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4185857/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou174.86
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky